Avenciguat Sales Forecast, and Market Size Analysis - 2034

Key Factors Driving Avenciguat Growth

1. Novel sGC Activator Mechanism Addressing NO-Independent Pathway

Soluble guanylate cyclase (sGC) activation

Avenciguat is a next-generation sGC activator, designed to work independently of nitric oxide (NO)-a major limitation in diseased tissues where NO signaling is impaired.

• Restores NO-sGC-cGMP signaling, improving endothelial function
• Active even under oxidative stress and hypoxia, where earlier sGC stimulators are less effective
• Strong differentiation vs. older agents (e.g., riociguat-like mechanisms)
• Broad applicability across vascular, renal, and fibrotic diseases

2. Demonstrated Clinical Activity in Chronic Kidney Disease (CKD)

Chronic kidney disease

• Randomized controlled trials showed significant reductions in albuminuria, a key biomarker of CKD progression
• Developed to slow kidney function decline and reduce cardiovascular risk
• CKD represents a large, chronic, high-burden market
• Biomarker-driven efficacy supports regulatory and clinical confidence

3. Multi-System Activity: Anti-Fibrotic, Anti-Inflammatory, and Vascular Effects

• Preclinical studies show:
• Reduction in TGF-B2 and CXCL4, key mediators of fibrosis
• Modulation of interferon (IFN-1) signaling and immune pathways
• Positions avenciguat as a multi-pathway disease-modifying therapy
• Enables expansion into systemic sclerosis, cirrhosis, and other fibrotic diseases

4. Broad Pipeline Across Multiple Indications

Systemic sclerosis

Avenciguat is being evaluated across several indications:

• CKD (clinical trials completed)
• Systemic sclerosis (Phase II - VITALISScE(TM) trial)
• Cirrhosis and portal hypertension (early-stage studies)
• Transition from single-indication asset -> multi-indication platform drug
• Expands total addressable market significantly

5. Favorable Pharmacokinetics and Safety Profile

• Clinical pharmacology studies show:
• ~83% oral absorption and high bioavailability
• Mostly mild adverse events, no discontinuations in early trials

Avenciguat Recent Developments

In February 2026, Boehringer Ingelheim signed a USD 500 million+ deal with Sitryx, to focus on immunometabolism therapies for autoimmune diseases, aiming for oral, targeted treatments.

"Avenciguat Sales Forecast, and Market Size Analysis - 2034" report provides comprehensive insights of Avenciguat for potential indication like Diabetic nephropathies, Portal hypertension, Renal failure, and Systemic scleroderma in the 7MM. A detailed picture of Avenciguat's existing usage in anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 -2034 is provided in this report along with a detailed description of the Avenciguat for potential indications. The Avenciguat market report provides insights about Avenciguat's sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current Avenciguat performance, future market assessments inclusive of the Avenciguat market forecast analysis for potential indications in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of Avenciguat sales forecasts, along with factors driving its market.

Avenciguat Drug Summary

Avenciguat is an investigational, orally administered soluble guanylate cyclase (sGC) activator being developed for the treatment of cardiovascular and renal diseases, particularly conditions associated with nitric oxide (NO)-sGC-cGMP pathway dysfunction such as chronic kidney disease and hypertension. It works by directly activating sGC independently of nitric oxide and also sensitizing the enzyme to endogenous NO, leading to increased production of cyclic guanosine monophosphate (cGMP), which promotes vasodilation, reduces inflammation, and inhibits fibrosis. Through these mechanisms, avenciguat has the potential to improve vascular function and organ protection. Early-phase clinical studies have demonstrated favorable pharmacokinetics and tolerability, and the drug is currently being evaluated in ongoing clinical trials to establish its efficacy and safety profile across cardiorenal indications. The report provides Avenciguat's sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the Avenciguat Market Report

The report provides insights into:

• A comprehensive product overview including the Avenciguat MoA, description, dosage and administration, research and development activities in potential indication like Diabetic nephropathies, Portal hypertension, Renal failure, and Systemic scleroderma.
• Elaborated details on Avenciguat regulatory milestones and other development activities have been provided in Avenciguat market report.
• The report also highlights Avenciguat's cost estimates and regional variations, reported and estimated sales performance, research and development activities in potential indications across the United States, Europe, and Japan.
• The Avenciguat market report also covers the patents information, generic entry and impact on cost cut.
• The Avenciguat market report contains current and forecasted Avenciguat sales for potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The Avenciguat market report also features the SWOT analysis with analyst views for Avenciguat in potential indications.

Methodology:

The Avenciguat market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Avenciguat Analytical Perspective by DelveInsight

• In-depth Avenciguat Market Assessment

This Avenciguat sales market forecast report provides a detailed market assessment of Avenciguat for potential indication like Diabetic nephropathies, Portal hypertension, Renal failure, and Systemic scleroderma in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted Avenciguat sales data uptil 2034.

• Avenciguat Clinical Assessment

The Avenciguat market report provides the clinical trials information of Avenciguat for potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

Avenciguat Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

Avenciguat Market Potential & Revenue Forecast

• Projected market size for the Avenciguat and its key indications
• Estimated Avenciguat sales potential (Avenciguat peak sales forecasts)
• Avenciguat Pricing strategies and reimbursement landscape

Avenciguat Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• Avenciguat Market positioning compared to existing treatments
• Avenciguat Strengths & weaknesses relative to competitors

Avenciguat Regulatory & Commercial Milestones

• Avenciguat Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

Avenciguat Clinical Differentiation

• Avenciguat Efficacy & safety advantages over existing drugs
• Avenciguat Unique selling points

Avenciguat Market Report Highlights

• In the coming years, the Avenciguat market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The Avenciguat companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence Avenciguat's dominance.
• Other emerging products for Diabetic nephropathies, Portal hypertension, Renal failure, and Systemic scleroderma are expected to give tough market competition to Avenciguat and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of Avenciguat in potential indications.
• Analyse Avenciguat cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted Avenciguat sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of Avenciguat in potential indications.

Key Questions:

• What is the class of therapy, route of administration and mechanism of action of Avenciguat? How strong is Avenciguat's clinical and commercial performance?
• What is Avenciguat's clinical trial status in each individual indications such as Diabetic nephropathies, Portal hypertension, Renal failure, and Systemic scleroderma and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Avenciguat Manufacturers?
• What are the key designations that have been granted to Avenciguat for potential indications? How are they going to impact Avenciguat's penetration in various geographies?
• What is the current and forecasted Avenciguat market scenario for potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of Avenciguat in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to Avenciguat for potential indications?
• Which are the late-stage emerging therapies under development for the treatment of potential indications?
• How cost-effective is Avenciguat? What is the duration of therapy and what are the geographical variations in cost per patient?